The European Medicines
Agency’s Pharmacovigilance Risk
Assessment Committee (PRAC) has
reviewed the identical medicines
Kogenate Bayer and Helixate
NexGen and concluded that
based on the full review of data
available including the RODIN and
EUHASS studies, the product is not
associated with increased risk of
developing factor VIII inhibitors
compared with other products.
For more details CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Dec 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.